A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Phase 2
Suspended
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: IV infusionOther: Placebo
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 16
- Registration Number
- NCT06833931
- Locations
- π¬π§
Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
π¬π§Oxford Children's Hospital, Oxford, United Kingdom
A Clinical Study of PGN-EDODM1 in People with Myotonic Dystrophy Type 1
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06667453
- Locations
- π¨π¦
CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
Phase 1
Recruiting
- Conditions
- Myotonic Dystrophy 1
- Interventions
- Drug: PGN-EDODM1 for infusionOther: Placebo
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 32
- Registration Number
- NCT06204809
- Locations
- πΊπΈ
UCI Center for Clinical Research, Irvine, California, United States
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈRare Disease Research, Atlanta, Georgia, United States
A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 7
- Registration Number
- NCT06079736
- Locations
- π¨π¦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
π¨π¦Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada
π¨π¦Children's Hospital of Eastern Ontario (CHEO), Ottawa, Ontario, Canada
Β© Copyright 2025. All Rights Reserved by MedPath